| Literature DB >> 28660286 |
Shuxi Ren1, Chunli Pang1, Yayue Huang1, Chengfen Xing1, Yong Zhan2, Hailong An3.
Abstract
Gain of function in mutations, D172N and E299V, of Kir2.1 will induce type III short QT syndrome. In our previous work, we had identified that a mixture of traditional Chinese medicine, styrax, is a blocker of Kir2.1. Here, we determined a monomer, hydrocinnamic acid (HA), as the effective component from 18 compounds of styrax. Our data show that HA can inhibit the currents of Kir2.1 channel in both excised inside-out and whole-cell patch with the IC50 of 5.21 ± 1.02 and 10.08 ± 0.46 mM, respectively. The time course of HA blockage and washout are 2.3 ± 0.6 and 10.5 ± 2.6 s in the excised inside-out patch. Moreover, HA can also abolish the currents of D172N and E299V with the IC50 of 6.66 ± 0.57 and 5.81 ± 1.10 mM for D172N and E299V, respectively. Molecular docking results determine that HA binds with Kir2.1 at K182, K185, and K188, which are phosphatidylinositol 4,5-bisphosphate (PIP2) binding residues. Our results indicate that HA competes with PIP2 to bind with Kir2.1 and inhibits the currents.Entities:
Keywords: Hydrocinnamic acid; Inhibitor; Kir2.1 channel; PIP2; SQT3
Mesh:
Substances:
Year: 2017 PMID: 28660286 DOI: 10.1007/s00232-017-9964-z
Source DB: PubMed Journal: J Membr Biol ISSN: 0022-2631 Impact factor: 1.843